Lv3
240 积分 2023-01-10 加入
Inavolisib: First Approval
2个月前
已完结
A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
5个月前
已完结
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
5个月前
已完结
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
5个月前
已完结
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
6个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
6个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
6个月前
已完结
Targeting DNA damage response pathways in cancer
6个月前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
6个月前
已完结
The Lancet Breast Cancer Commission
6个月前
已完结
皖公网安备34019202002308
